Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-07-07T18:01:11.489Z Has data issue: false hasContentIssue false
  • English
  • Français

PHARMACOECONOMIC STUDIES IN WORLD HEALTH ORGANIZATION EASTERN MEDITERRANEAN COUNTRIES: REPORTING COMPLETENESS

Published online by Cambridge University Press:  05 June 2017

Qais Alefan  and
Karen Rascati
Qais Alefan
Affiliation:
Jordan University of Science and [email protected]
Karen Rascati
Affiliation:
College of Pharmacy, The University of Texas at Austin
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to evaluate the extent of reporting necessary information in published health economic research in World Health Organization Eastern Mediterranean Countries (WHO EMC).

Methods: A systematic literature search was conducted using PubMed and Google Scholar to identify pharmacoeconomic studies conducted in WHO EMC. The inclusion criteria for the studies were: (i) original studies, (ii) compared pharmaceutical services or drugs, (iii) conducted in WHO EMC, (iv) manuscript published in English. The articles were reviewed by two independent reviewers using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.

Results: A total of seventeen studies were included, each of which were published in seventeen different journals. The mean CHEERS checklist score was 16 ± 4. Most studies were published in journals outside WHO EMC (n = 12; 71 percent). Cost-effectiveness (n = 5; 29 percent) and cost-utility analyses (n = 5; 29 percent) were the most frequently used methods of economic evaluation.

Conclusions: Pharmacoeconomic studies in WHO EMC are limited and sometimes incomplete. Economic evaluation of pharmaceuticals should be encouraged in WHO EMC to ensure the appropriate allocation of healthcare resources.

Keywords

Developing countriesCost-effectiveness analysis (CEA)PharmacoeconomicsReview
Type
Assessments
Information
International Journal of Technology Assessment in Health Care , Volume 33 , Issue 2 , 2017 , pp. 215 - 221
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. WHO regional office for the eastern Mediterranean (Internet). Switzerland: World Health Organization, 2016. http://www.emro.who.int/countries.html (accessed February 17, 2016).Google Scholar
2. Boncz, I, Kaló, K, Mohamed Ibrahim, MI, Greenberg, D. Further steps in the development of pharmacoeconomics, outcomes research, and health technology assessment in central and eastern Europe, Western Asia, and Africa. Value Health Reg Issues. 2013;2:169–170.Google Scholar
3. Health economics and health care financing. WHO regional office for the eastern Mediterranean (Internet). Switzerland: World Health Organization, 2016. http://www.emro.who.int/entity/health-economics/index.html (accessed February 17, 2016).Google Scholar
4. Desai, PR, Chandwani, HS, Rascati, KL. Assessing the quality of pharmacoeconomic studies in India: A systematic review. Pharmacoeconomics. 2012;30:749–762.Google Scholar
5. Hjelmgren, J, Berggren, F, Andersson, F. Health economic guidelines-similarities, differences and some implications. Value Health. 2001;4:225–250.CrossRefGoogle ScholarPubMed
6. Jacobs, P, Bachynsky, J, Baladi, JF. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics. 1995;8:182–9.Google Scholar
7. Walker, D, Fox-Rushby, JA. Economic evaluation of communicable disease interventions in developing countries: A critical review of the published literature. Health Econ. 2000;9:681–698.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
8. EUnetHTA methodological guideline - Methods for health economic evaluations. http://www.eunethta.eu/outputs/eunethta-methodological-guideline-methods-health-economic-evaluations (accessed December 16, 2016).Google Scholar
9. Pharmacoeconomic Guidelines around the World. http://www.ispor.org/PEguidelines/index.asp Google Scholar
10. Lee, KS, Brouwer, WB, Lee, SI, Koo, HW. Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information?: A critical review of published Korean economic evaluations. Pharmacoeconomics. 2005;23:709–721.Google Scholar
11. Gavaza, P, Rascati, KL, Lawson, K, Lawson, K, Mann, T. The state of health economics and pharmacoeconomics research in Zimbabwe: A review. Curr Ther Res Clin Exp. 2008;69:268–285.Google Scholar
12. Gavaza, P, Rascati, KL, Oladapo, AO, Khoza, S. The state of health economic evaluation research in Nigeria: A systematic review. Pharmacoeconomics. 2010;28:539–553.CrossRefGoogle ScholarPubMed
13. Hoque, ME, Khan, JA, Hossain, SS, et al. A systematic review of economic evaluations of health and health-related interventions in Bangladesh. Cost Eff Resour Alloc. 2011;9:12.Google Scholar
14. Gavaza, P, Rascati, KL, Oladapo, AO, Khoza, S. The state of health economic research in South Africa: A systematic review. Pharmacoeconomics. 2012;30:925–940.CrossRefGoogle ScholarPubMed
15. Machado, M, Iskedjian, M, Einarson, TR. Quality assessment of published health economic analyses from South America. Ann Pharmacother. 2006;40:943–949.Google Scholar
16. Teerawattananon, Y, Russel, S, Mugford, M. A systemic review of economic evaluation literature in Thailand: Are the data good enough to be used by policy makers? Pharmacoeconomics. 2007;25:467–479.Google Scholar
17. Gavaza, P, Shepherd, M, Shcherbakova, N, Khoza, S. The state of health economics and pharmacoeconomics research in Russia: A systematic review. J Pharm Health Serv Res. 2010;1:113–121.Google Scholar
18. Jiang, S, Ma, X, Desai, P, Yang, L, Rascati, K. A systematic review on the extent and quality of pharmacoeconomic publications for China. Value Health Reg Issues. 2014;3:79–86.Google Scholar
19. Husereau, D, Drummond, M, Petrou, S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–250.Google Scholar
20. Alefan, Q, AlImam, S, Mukattash, T, Mhaidat, N, Alabbadi, I, Rascati, K. Pharmacoeconomics education in WHO Eastern Mediterranean region. Curr Pharm Teach Learn. 2015;7:819–825.Google Scholar
21. Garattini, L, De Compadri, P, Clemente, R, Cornago, D. Economic evaluations in Italy: A review of the literature. Int J Technol Assess Health Care. 2003;19:685–737.Google Scholar
Supplementary material: File

Alefan and Rascati supplementary material

Table S1

Download Alefan and Rascati supplementary material(File)
File 15.6 KB